1. 1. Angelin B, Einarsson K, Hellstrom K, Leijd B (1978) Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. J Lipid Res 19: 1017–1024 - PubMed
2. 1. Brendel C, Schoonjans K, Botrugno OA, Treuter E, Auwerx J (2002) The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. Mol Endocrinol 16: 2065–2076 - PubMed
3. 1. Chiang JY (2002) Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 23: 443–463 - PubMed
4. 1. Claudel T, Staels B, Kuipers F (2005) The farnesoid X receptor. A molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 25: 2020–2030 - PubMed
5. 1. Cohen DE (2003) Pathogenesis of gallstones. In Hepatology: A Textbook of Liver Disease, Zakim D, Boyer TD (eds) pp 1713–1743. Philadelphia: Saunders
6. 1. Cui J, Huang L, Zhao A, Lew JL, Yu J, Sahoo S, Meinke PT, Royo I, Pelaez F, Wright SD (2003) Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem 278: 10214–10220 - PubMed
7. 1. De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M (2003) Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 278: 39124–39132 - PubMed
8. 1. Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR, Bowman ME, Ferrer JL, Anisfeld AM, Edwards PA, Rosenfeld JM, Alvarez JG, Noel JP, Nicolaou KC, Evans RM (2003) A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 11: 1079–1092 - PMC - PubMed
9. 1. Duran-Sandoval D, Cariou B, Percevault F, Hennuyer N, Grefhorst A, van Dijk TH, Gonzalez FJ, Fruchart JC, Kuipers F, Staels B (2005) The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting–refeeding transition. J Biol Chem 280: 29971–29979 - PubMed
10. 1. Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, Fruchart JC, Kuipers F, Staels B (2004) Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 53: 890–898 - PubMed
11. 1. Dussault I, Beard R, Lin M, Hollister K, Chen J, Xiao JH, Chandraratna R, Forman BM (2003) Identification of gene-selective modulators of the bile acid receptor FXR. J Biol Chem 278: 7027–7033 - PubMed
12. 1. Engelking LR, Dasher CA, Hirschowitz BI (1980) Within-day fluctuations in serum bile-acid concentrations among normal control subjects and patients with hepatic disease. Am J Clin Pathol 73: 196–201 - PubMed
13. 1. Everson GT (1987) Steady-state kinetics of serum bile acids in healthy human subjects: single and dual isotope techniques using stable isotopes and mass spectrometry. J Lipid Res 28: 238–252 - PubMed
14. 1. Foretz M, Pacot C, Dugail I, Lemarchand P, Guichard C, Le Liepvre X, Berthelier-Lubrano C, Spiegelman B, Kim JB, Ferre P, Foufelle F (1999) ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell Biol 19: 3760–3768 - PMC - PubMed
15. 1. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, Evans RM, Weinberger C (1995) Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81: 687–693 - PubMed
16. 1. Francis GA, Fayard E, Picard F, Auwerx J (2003) Nuclear receptors and the control of metabolism. Annu Rev Physiol 65: 261–311 - PubMed
17. 1. Garg A, Grundy SM (1994) Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 121: 416–422 - PubMed
18. 1. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6: 517–526 - PubMed
19. 1. Grundy SM, Ahrens EH Jr, Salen G (1971) Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med 78: 94–121 - PubMed
20. 1. Gupta S, Stravitz RT, Dent P, Hylemon PB (2001) Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J Biol Chem 276: 15816–15822 - PubMed
21. 1. Hinuma S, Fujii R, Kawamata Y, Komatsu H, Ueshima M, Ito F (2005) Screening method (method for the screening of agonists or antagonists of TGR5). 2003-380574[P2005-21151A (JP)]
22. 1. Ho KJ (1976) Circadian distribution of bile acid in the enterohepatic circulatory system in hamsters. J Lipid Res 17: 600–604 - PubMed
23. 1. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang da Y, Mansfield TA, Kliewer SA, Goodwin B, Jones SA (2003) Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17: 1581–1591 - PMC - PubMed
24. 1. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1125–1131 - PMC - PubMed
25. 1. Houten SM, Auwerx J (2004) The enterohepatic nuclear receptors are major regulators of the enterohepatic circulation of bile salts. Ann Med 36: 482–491 - PubMed
26. 1. Hung CC, Farooqi IS, Ong K, Luan J, Keogh JM, Pembrey M, Yeo GS, Dunger D, Wareham NJ, O'Rahilly S (2003) Contribution of variants in the small heterodimer partner gene to birthweight, adiposity, and insulin levels. Diabetes 52: 1288–1291 - PubMed
27. 1. Ikemoto S, Takahashi M, Tsunoda N, Maruyama K, Itakura H, Kawanaka K, Tabata I, Higuchi M, Tange T, Yamamoto TT, Ezaki O (1997) Cholate inhibits high-fat diet-induced hyperglycemia and obesity with acyl-CoA synthetase mRNA decrease. Am J Physiol 273: 37–45 - PubMed
28. 1. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2: 217–225 - PubMed
29. 1. Kanaya E, Shiraki T, Jingami H (2004) The nuclear bile acid receptor FXR is activated by PGC-1alpha in a ligand-dependent manner. Biochem J 382: 913–921 - PMC - PubMed
30. 1. Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, Reue K, Gonzalez FJ, Willson TM, Edwards PA (2001) Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 15: 1720–1728 - PubMed
31. 1. Katsuma S, Hirasawa A, Tsujimoto G (2005) Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329: 386–390 - PubMed
32. 1. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y, Fujino M (2003) A G protein-coupled receptor responsive to bile acids. J Biol Chem 278: 9435–9440 - PubMed
33. 1. Kerr TA, Saeki S, Schneider M, Schaefer K, Berdy S, Redder T, Shan B, Russell DW, Schwarz M (2002) Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev Cell 2: 713–720 - PMC - PubMed
34. 1. Koo SH, Satoh H, Herzig S, Lee CH, Hedrick S, Kulkarni R, Evans RM, Olefsky J, Montminy M (2004) PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med 10: 530–534 - PubMed
35. 1. Lee H, Zhang Y, Lee FY, Nelson SF, Gonzalez FJ, Edwards PA (2006) FXR regulates organic solute transporters {alpha} and {alpha} in the adrenal gland, kidney, and intestine. J Lipid Res 47: 201–214 - PubMed
36. 1. Leiss O, von Bergmann K (1982) Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones. Scand J Gastroenterol 17: 587–592 - PubMed
37. 1. Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, MacKenzie KI, Mansfield TA, Kliewer SA, Goodwin B, Jones SA (2003) Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 112: 1678–1687 - PMC - PubMed
38. 1. Lowell BB, Shulman GI (2005) Mitochondrial dysfunction and type 2 diabetes. Science 307: 384–387 - PubMed
39. 1. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6: 507–515 - PubMed
40. 1. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B (1999) Identification of a nuclear receptor for bile acids. Science 284: 1362–1365 - PubMed
41. 1. Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD, Creech KL, Moore LB, Wilson JG, Lewis MC, Jones SA, Willson TM (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 43: 2971–2974 - PubMed
42. 1. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Itadani H, Tanaka K (2002) Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 298: 714–719 - PubMed
43. 1. Meyer U, Costantino G, Macchiarulo A, Pellicciari R (2005) Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study. J Med Chem 48: 6948–6955 - PubMed
44. 1. Miller NE, Nestel PJ (1974) Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. Lancet 2: 929–931 - PubMed
45. 1. Mitchell SM, Weedon MN, Owen KR, Shields B, Wilkins-Wall B, Walker M, McCarthy MI, Frayling TM, Hattersley AT (2003) Genetic variation in the small heterodimer partner gene and young-onset type 2 diabetes, obesity, and birth weight in UK subjects. Diabetes 52: 1276–1279 - PubMed
46. 1. Moschetta A, Bookout AL, Mangelsdorf DJ (2004) Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med 10: 1352–1358 - PubMed
47. 1. Nestel PJ, Grundy SM (1976) Changes in plasma triglyceride metabolism during withdrawal of bile. Metabolism 25: 1259–1268 - PubMed
48. 1. Nishigori H, Tomura H, Tonooka N, Kanamori M, Yamada S, Sho K, Inoue I, Kikuchi N, Onigata K, Kojima I, Kohama T, Yamagata K, Yang Q, Matsuzawa Y, Miki T, Seino S, Kim MY, Choi HS, Lee YK, Moore DD, Takeda J (2001) Mutations in the small heterodimer partner gene are associated with mild obesity in Japanese subjects. Proc Natl Acad Sci USA 98: 575–580 - PMC - PubMed
49. 1. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284: 1365–1368 - PubMed
50. 1. Pellicciari R, Costantino G, Fiorucci S (2005) Farnesoid X receptor: from structure to potential clinical applications. J Med Chem 48: 5383–5403 - PubMed
51. 1. Qiao L, Han SI, Fang Y, Park JS, Gupta S, Gilfor D, Amorino G, Valerie K, Sealy L, Engelhardt JF, Grant S, Hylemon PB, Dent P (2003) Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes. Mol Cell Biol 23: 3052–3066 - PMC - PubMed
52. 1. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ (2000) Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 14: 2819–2830 - PMC - PubMed
53. 1. Russell DW (2003) The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72: 137–174 - PubMed
54. 1. Savkur RS, Thomas JS, Bramlett KS, Gao Y, Michael LF, Burris TP (2005) Ligand-dependent coactivation of the human bile acid receptor FXR by the peroxisome proliferator-activated receptor gamma coactivator-1alpha. J Pharmacol Exp Ther 312: 170–178 - PubMed
55. 1. Schoenfield LJ, Lachin JM (1981) Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Ann Intern Med 95: 257–282 - PubMed
56. 1. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B (2000) Role of LXRs in control of lipogenesis. Genes Dev 14: 2831–2838 - PMC - PubMed
57. 1. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL (1999) Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci USA 96: 13656–13661 - PMC - PubMed
58. 1. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102: 731–744 - PubMed
59. 1. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF, Burris TP (2005) Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146: 984–991 - PubMed
60. 1. Szapary PO, Wolfe ML, Bloedon LT, Cucchiara AJ, DerMarderosian AH, Cirigliano MD, Rader DJ (2003) Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 290: 765–772 - PubMed
61. 1. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D, Stewart TA (2002) Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143: 1741–1747 - PubMed
62. 1. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD (2002) A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296: 1703–1706 - PubMed
63. 1. Wang H, Chen J, Hollister K, Sowers LC, Forman BM (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3: 543–553 - PubMed
64. 1. Wang L, Lee YK, Bundman D, Han Y, Thevananther S, Kim CS, Chua SS, Wei P, Heyman RA, Karin M, Moore DD (2002) Redundant pathways for negative feedback regulation of bile acid production. Dev Cell 2: 721–731 - PubMed
65. 1. Wang L, Liu J, Saha P, Huang J, Chan L, Spiegelman B, Moore DD (2005) The orphan nuclear receptor SHP regulates PGC-1alpha expression and energy production in brown adipocytes. Cell Metab 2: 227–238 - PubMed
66. 1. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439: 484–489 - PubMed
67. 1. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J (2004) Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113: 1408–1418 - PMC - PubMed
68. 1. Wu J, Xia C, Meier J, Li S, Hu X, Lala DS (2002) The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. Mol Endocrinol 16: 1590–1597 - PubMed
69. 1. Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J, Fukamizu A (2004) Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 279: 23158–23165 - PubMed
70. 1. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA (2004) Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 18: 157–169 - PMC - PubMed
71. 1. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA (2006) Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 103: 1006–1011 - PMC - PubMed